Celgene Corp | StockChase
67
Celgene Corp (CELG-Q)

Last Price Recorded: $79.4400 on 2018-06-20

ON STOCKCHASE SINCE Jan 2012

Consumer Products
67
Celgene Corp (CELG-Q)

Last Price Recorded: $79.4400 on 2018-06-20

ON STOCKCHASE SINCE Jan 2012

Consumer Products

Celgene Corp


Signal Opinion Expert
BUY
Celgene Corp(CELG-Q) 

June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock.  This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.  

Consumer Products

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock.  This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.  

Consumer Products
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$78.390
Owned Owned
Unknown

TOP PICK
Celgene Corp(CELG-Q) 

May 30, 2018

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Consumer Products

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Consumer Products
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$77.970
Owned Owned
Yes

PAST TOP PICK
Celgene Corp(CELG-Q) 

May 28, 2018

(A Top Pick May 28/17, Down 32%)  It is considered best of class but stumbled and there is a negative sentiment to health care stocks.  It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Consumer Products

(A Top Pick May 28/17, Down 32%)  It is considered best of class but stumbled and there is a negative sentiment to health care stocks.  It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Consumer Products
Teal Linde

Portfolio , Linde Equity Report...

Price Price
$78.630
Owned Owned
Yes

DON'T BUY
Celgene Corp(CELG-Q) 

May 28, 2018

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

Consumer Products

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

Consumer Products
Wolfgang Klein

Senior inv, Canaccord Genuity We...

Price Price
$78.630
Owned Owned
No

DON'T BUY
Celgene Corp(CELG-Q) 

May 24, 2018

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

Consumer Products

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

Consumer Products
Stan Wong

Director &, Private Wealth Manag...

Price Price
$78.630
Owned Owned
No

DON'T BUY
Celgene Corp(CELG-Q) 

May 9, 2018

They completed a $5 billion buyback recently.  They put up a beat on recent earnings, but there were concerns about future earnings.  He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum.  They have great forecasted cash flow, but watch out if they miss their guidance. 

Consumer Products

They completed a $5 billion buyback recently.  They put up a beat on recent earnings, but there were concerns about future earnings.  He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum.  They have great forecasted cash flow, but watch out if they miss their guidance. 

Consumer Products
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$82.800
Owned Owned
No

BUY
Celgene Corp(CELG-Q) 

April 30, 2018

We have some erosion here.  You have to live with the overreaction.  Around the $75 - $85 range there is probably a really good opportunity. 

Consumer Products

We have some erosion here.  You have to live with the overreaction.  Around the $75 - $85 range there is probably a really good opportunity. 

Consumer Products
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$87.100
Owned Owned
Unknown

HOLD
Celgene Corp(CELG-Q) 

April 25, 2018

A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of  getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.

Consumer Products

A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of  getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.

Consumer Products
Gordon Reid

President, GoodReid Investment ...

Price Price
$89.200
Owned Owned
Yes

SELL ON STRENGTH
Celgene Corp(CELG-Q) 

April 2, 2018

It broke down in a lousy earnings report late last year.  It broke its trend line, and more importantly the level of support at $97 has been broken.  There is a lot of air or space now below this price.  He is concerned about the look of it from a technical perspective.  It might pop back up to its previous support level.

Consumer Products

It broke down in a lousy earnings report late last year.  It broke its trend line, and more importantly the level of support at $97 has been broken.  There is a lot of air or space now below this price.  He is concerned about the look of it from a technical perspective.  It might pop back up to its previous support level.

Consumer Products
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$87.070
Owned Owned
Unknown

PAST TOP PICK
Celgene Corp(CELG-Q) 

March 21, 2018

(A Top Pick  May  10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.

Consumer Products

(A Top Pick  May  10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.

Consumer Products
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$88.310
Owned Owned
Yes

TOP PICK
Celgene Corp(CELG-Q) 

March 21, 2018

Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)

Consumer Products

Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)

Consumer Products
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$88.310
Owned Owned
Yes

TOP PICK
Celgene Corp(CELG-Q) 

March 20, 2018

Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)

Consumer Products

Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)

Consumer Products
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$88.270
Owned Owned
Yes

BUY
Celgene Corp(CELG-Q) 

March 13, 2018

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term. 

Consumer Products

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term. 

Consumer Products
Stan Wong

Director &, Private Wealth Manag...

Price Price
$91.560
Owned Owned
Yes

PAST TOP PICK
Celgene Corp(CELG-Q) 

January 15, 2018

(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.

Consumer Products

(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.

Consumer Products
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$106.000
Owned Owned
Yes

PAST TOP PICK
Celgene Corp(CELG-Q) 

December 7, 2017

(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.

Consumer Products

(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.

Consumer Products
Stan Wong

Director &, Private Wealth Manag...

Price Price
$102.730
Owned Owned
Yes

Showing 1 to 15 of 67 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company